BEDFORD, Mass., Aug. 22 /PRNewswire-FirstCall/ -- Hologic, Inc. , a leading provider of state-of-the-art diagnostic and digital imaging systems directed towards women’s health, today announced the publication of the first large scale study comparing the results of a particular digital mammography technology to women screened with film. The Vestfold County Study by E. Vigeland, H. Klaasen, T.A. Klingen, S. Hofvind and P. Skaane was published in the on line version of European Radiology in August 2007. The researchers compared cancer detection and recall rates of 18,239 women screened with a Hologic Selenia digital mammography system to the results of 324,763 women screened with film over a two year period.
While prior studies have compared the performance of digital mammography to screen-film in high volume screening, until this study no researchers had looked at the performance of a specific digital mammography technology. The detector characteristics and way the various digital mammography systems operate is considerably different. The pixel size of the system studied, the Hologic Selenia system, is smaller, the system uses direct capture (selenium) technology, and the image-processing algorithms are unique, resulting in a sharp, high contrast image.
The researchers reported that the detection rate for ductal carcinoma in situ (DCIS) and the positive predictive value for cancer (PPV) were statistically significantly higher and the technical recall rate was statistically lower for Selenia over film.
A copy of this study may be found at http://www.springerlink.com/content/07kv61u3465325x0/.
About Hologic
Hologic Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic is the recognized leader in the development and commercialization of computer-aided detection (CAD), an innovative technology that assists physicians in the earlier detection of breast cancer. For more information, visit http://www.hologic.com .
Forward Looking Disclaimer
This release contains forward-looking information that involves risks and uncertainties, including statements regarding Hologic’s plans, objectives, expectations and intentions. Such statements include, without limitation, statements regarding the benefits and performance of Hologic’s Selenia digital mammography system. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated. Factors that could cause actual results to materially differ include, without limitation, uncertainties inherent in the development of new products and the enhancement of existing products, including technical and regulatory risks, cost overruns and delays; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; the early stage of market development for digital mammography products; technical innovations that could render products marketed or under development by Hologic obsolete; competition; and other factors described in Hologic’s filings with the SEC. Other factors that could adversely affect Hologic’s business and prospects are described in Hologic’s filings with the Securities and Exchange Commission. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Hologic’s expectations or any change in events, conditions or circumstances on which any such statement is based.
Contact: Glenn P. Muir Frances Crecco Executive Vice President & CFO Director, Investor Relations Hologic, Inc. Hologic, Inc. (781) 999-7300 (781) 999-7377
Hologic, Inc.
CONTACT: Glenn P. Muir, Executive Vice President & CFO, +1-781-999-7300,or Frances Crecco, Director, Investor Relations, +1-781-999-7377, both ofHologic, Inc.
